Solid Biosciences Q4 net loss widens on higher R&D costs

Overview

• US genetic medicine developer's Q4 net loss widened yr/yr, driven by higher R&D expenses

Outlook

• Solid anticipates cash runway to extend into H1 2028 after $240 mln private placement

Result Drivers

• SGT-003 COSTS - Higher R&D expenses were mainly due to increased manufacturing and clinical costs for SGT-003

• PERSONNEL EXPENSES - R&D and G&A expenses rose due to higher personnel-related costs

• PIPELINE ADVANCEMENT - Increased expenses also reflected progress in other pipeline programs, including SGT-601 and SGT-501

Company press release: ID:nGNX6lWz98

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 124.7% above its March 18 closing price of $7.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.